CS-SINS Antibody Screening via Plasmon Shifts
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing monoclonal antibody developability, particularly for subcutaneous administration, face challenges due to high viscosity, opalescence, and aggregation issues, which are difficult to predict at ultra-dilute concentrations, leading to resource-intensive mitigation strategies and delayed development.
Innovation Solution
The use of positively-charged polymers to stabilize nanoparticles with capture agents, allowing for the detection of protein self-association characteristics in ultra-dilute solutions through charge-stabilized self-interaction nanoparticle spectroscopy (CS-SINS), which measures plasmon wavelength shifts to predict problematic solution behaviors at higher concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentration formulations are used for subcutaneous administration, then therapeutic efficacy is improved, but solution behavior deteriorates (high viscosity, opalescence, phase separation, and aggregation)
Solution Approach 1:
The patent applies preliminary action by assessing antibody self-association properties at ultra-dilute concentrations during early discovery stages, before formulation development. This allows identification of antibodies with favorable solution properties beforehand, preventing later formulation issues without requiring high concentration testing initially.
Solution Approach 2:
The patent replaces traditional mechanical/visual assessment methods (requiring high concentration formulations to observe viscosity and aggregation) with optical measurement techniques (light scattering spectroscopy) that can detect self-association at ultra-dilute concentrations through plasmon wavelength shifts.
2Measurement precision
If traditional assessment methods are used for antibody self-association, then measurement accuracy is improved, but resource consumption increases and development time extends
Solution Approach 1:
The patent enables preliminary assessment of antibody self-association properties at the earliest discovery stages using ultra-dilute solutions, eliminating the need for time-consuming high concentration formulation development and subsequent mitigation strategies.
Solution Approach 2:
The patent substitutes resource-intensive traditional assessment methods with rapid optical measurement techniques that can evaluate self-association properties in ultra-dilute solutions, significantly reducing development time and resource consumption while maintaining measurement accuracy.
3Loss of substance
If ultra-dilute solution measurements are used, then resource consumption is reduced, but measurement sensitivity deteriorates
Solution Approach 1:
The patent replaces conventional measurement techniques with light scattering spectroscopy that detects plasmon wavelength shifts in nanoparticles, enabling sensitive detection of self-association at ultra-dilute concentrations where traditional methods would fail.
Solution Approach 2:
The patent uses nanoparticles as intermediaries that amplify the signal. The nanoparticles interact with light to produce measurable plasmon wavelength shifts that reflect antibody self-association, enabling detection at ultra-dilute concentrations without requiring large amounts of sample material.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
CS-SINS enables the identification of antibodies with favorable self-association properties at early stages, reducing the risk of complications during manufacturing and formulation, thereby accelerating development timelines and reducing resource expenditures.
Implementation Method 1
the use of a positively-charged polymer to stabilize a nanoparticle comprising a capture agent on the surface
Implementation Method 2
measuring the absorbance of light of the target protein conjugate at multiple wavelengths ranging from 450 nm to about 750 nm; and identifying a plasmon wavelength as the wavelength at which there is maximal absorbance
Data Source
AI summary
The present disclosure provides means such as uses, nanoparticles, solutions, methods, kits and systems for screening target proteins for self-association properties (viscosity and opalescence) in ultra-dilute solutions. They provide means for screening a large number of target proteins at orders of magnitude lower concentrations than end-use formulations.